Abstracts tagged "rheumatoid arthritis"

Abstract Number: LB05 • ACR Convergence 2025
ER Stress-Induced ATP2A3 Drives Rheumatoid Arthritis via Activation of STING Signaling
yujie cai, Nanfang hospital, Guangzhou, China (People's Republic)
Background/Purpose: Rheumatoid arthritis (RA) is an autoimmune disease characterized by persistent synovial inflammation and joint bone destruction. Endoplasmic reticulum (ER) stress plays an important role…
Abstract Number: LB15 • ACR Convergence 2025
Dietary Fiber Supplementation Enhances Methotrexate Response and Restores Th17/Treg Balance in Rheumatoid Arthritis: Results from the Superfibre Randomized Trial
Claire Immediato Daien¹, Jean-Pierre Hellier², Zübeyir Salis³, Gaël Mouterde⁴, Jacques Morel⁵, Laurence Macia⁶ and Rachel audo⁴, ¹CHU and Univesrity of Montpellier, Montpellier, France, ²CHU Montpellier, Arles, France, ³University of Montpellier, Montpellier, France, ⁴CHU Montpellier, Montpellier, France, ⁵CHU and University of Montpellier, Montpellier, France, ⁶Sydney University, Brisbane, Australia
Background/Purpose: Gut dysbiosis and Th17/Treg imbalance contribute to rheumatoid arthritis (RA). Additionally, methotrexate (MTX) efficacy depends on gut microbiota composition, especially on the presence of B.…
Abstract Number: LB19 • ACR Convergence 2025
Rosnilimab, a Selective and Potent Depleter of Pathogenic T Cells, Demonstrates Efficacy, Safety, and Translational Proof of Mechanism in a Rheumatoid Arthritis Phase 2B Trial
Jonathan Graf¹, Amy Archer², Sergiy Kovalenko³, Katarzyna Kolossa⁴, John Serpa⁵, Tamta Kobakhidze⁶, Daniela Cepoi⁷, Andrea Everding⁸, Costantino Pitzalis⁹, Catherine Aversa², Martin Dahl², May Hafez², Paul Lizzul², Priya Raina², Bruce Randazzo², Yangsu Ren², Khalil Saikali², Cailin Sibley¹⁰, Gerd Burmester¹¹, Jacques-eric GOTTENBERG¹², Iain McInnes¹³, Eduardo Mysler¹⁴, Lee Simon¹⁵, Josef Smolen¹⁶, Jeffrey Sparks¹⁷, Ronald van Vollenhoven¹⁸, Michael Weinblatt¹⁹ and Paul Emery²⁰, ¹UCSF, San Francisco, California, ²AnaptysBio Inc, San Diego, California, ³Arensia Exploratory Medicine, Kyiv, Ukraine, ⁴MICS Centrum Medyczne, Bydgoszcz, Poland, ⁵Allied Biomedical Research Institute, Miami, Florida, ⁶Research Institute of Clinical Medicine Todua Clinic, Tbilisa, Georgia, ⁷Nicolae Testemitanu State University of Medicine & Pharmacy, Chisinau, Moldova, ⁸MVZ Rheumatologie & Autoimmunmedzin Hamburg GmbH, Hamburg, Germany, ⁹QMUL, Bromley Kent, United Kingdom, ¹⁰AnaptysBio Inc, San Diego, ¹¹Charité - Universitétsmedizin Berlin, Berlin, Germany, ¹²Hautepierre Hospital, STRASBOURG, France, ¹³University of Glasgow, Glasgow, United Kingdom, ¹⁴OMI, Buenos Aires, Argentina, ¹⁵SDG LLC, West Newton, Massachusetts, ¹⁶Medical University of Vienna, Vienna, Austria, ¹⁷Brigham and Women's Hospital, Boston, Massachusetts, ¹⁸Amsterdam UMC, Amsterdam, Netherlands, ¹⁹Brigham and Women's Hospital/ Harvard Medical School, Waban, Massachusetts, ²⁰University of Leeds, Leeds, United Kingdom
Background/Purpose: Over 50% of RA patients require multiple b/tsDMARD classes due to inadequate or lost response. Rosnilimab, an investigational monoclonal antibody that selectively targets and…
Abstract Number: LB23 • ACR Convergence 2025
A Phase 1 Study of Autologous CAR-Treg Cells in Refractory Rheumatoid Arthritis: Interim Report of Safety and Efficacy
Minna Kohler¹, Sally Arai², Fawad Aslam³, Gregory Challener⁴, Matthew Frigault⁴, Melissa Griffith⁵, Tamiko Katsumoto⁶, Elena Massarotti⁷, Larry Moreland⁸, Allison Rosenthal⁹, Jeffrey Sparks⁷, Janeth Yinh⁴, Sarah Baxter¹⁰, Ari Bitton¹¹, Jason Dubovsky¹², Victor Yuan¹³, Mindy Jensen¹⁴, Andrew Clauw¹⁵, Gabrielle Furman⁴, Rita Gyurko⁷, Megan Hall⁹, Anna McIntyre⁴, Jennifer Seifert¹⁶, Emma Stainton², Michelle Blake¹⁰, Sabrina Fox-Bosetti¹³, Herve Lebrec¹³, Amanda Pace¹⁰, Yuanyuan Xiao¹⁷, Mei-Lun Wang¹⁸, Joe Arron¹³ and Jeffrey Bluestone¹⁹, ¹Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, ²Stanford, Palo Alto, California, ³Mayo Clinic, Arizona, Scottsdale, Arizona, ⁴Massachusetts General Hospital, Boston, Massachusetts, ⁵University of Colorado Anschutz Medical Campus, Aurora, Colorado, ⁶Stanford University, Millbrae, California, ⁷Brigham and Women's Hospital, Boston, Massachusetts, ⁸University of Colorado, Denver, Colorado, ⁹Mayo Clinic, Phoenix, Arizona, ¹⁰Sonoma Biotherapeutics, Seattle, Washington, ¹¹Sonoma Biotherapeutics, San Diego, California, ¹²Sonoma Biotherapeutics, Thousand Oaks, California, ¹³Sonoma Biotherapeutics, South San Francisco, California, ¹⁴Sonoma Bio, Seattle, Washington, ¹⁵University of Colorado, Aurora, Colorado, ¹⁶University of Colorado and Oklahoma Medical Research Foundation, Aurora, Colorado, ¹⁷Sonoma Biotherapeutics, Los Altos, California, ¹⁸Sonoma Biotherapeutics, San Francisco, California, ¹⁹Sonoma Biotherapeutics Inc, South San Francisco, California
Background/Purpose: Regulatory T cells (Tregs) modulate inflammation, maintain self-tolerance, promote tissue repair, and hold promise as a versatile therapeutic. Autologous polyclonal Tregs have a favorable…
Abstract Number: 1347 • ACR Convergence 2025
The Better Disease-modifying antirheumatic drug (DMARD)? Efficacy and Safety of Methotrexate Versus Leflunomide Monotherapy in Rheumatoid Arthritis: A Systematic Review and Meta-Analysis
Aakanksha Pitliya¹, Srivatsa Surya Vasudevan², Sarthak Sharma³, Bijay Mukesh Jeswani⁴, Tanya Ratnani⁵ and Rajesh Thirumaran⁶, ¹Mercy Catholic Medical Center, Darby, PA, Clifton Heights, PA, ²Louisiana State University Health Sciences Center, Shreveport, LA, ³Government Medical College, Jammu, Jammu, Jammu and Kashmir, India, ⁴GCS Medical College, Hospital and Research Center, Ahmedabad, Gujarat, India, ⁵Chhattisgarh Institute of Medical Sciences, Bilaspur, Chhattisgarh, India, ⁶Mercy Catholic Medical Center, Darby, PA
Background/Purpose: Methotrexate (MTX) and leflunomide (LEF) are commonly used disease-modifying antirheumatic drugs (DMARDs) in the treatment of rheumatoid arthritis (RA). While both are widely prescribed,…
Abstract Number: 1330 • ACR Convergence 2025
Sex and reproductive stage modify the role of endogenous estrogens on coronary atherosclerosis in rheumatoid arthritis and differences reflect effects on inflammation and cholesterol metabolism
George Karpouzas¹, Bianca Papotti², Sarah Ormseth³, Marcella Palumbo², Matthew Budoff¹ and Nicoletta Ronda², ¹Harbor-UCLA Medical Center, Torrance, CA, ²University of Parma, Parma, Italy, ³The Lundquist Institute for Biomedical Innovation, Torrance, CA
Background/Purpose: Endogenous estrogens associate with cardioprotective benefits in the general population. Yet, dual pro- and anti-inflammatory effects were described in autoimmune states depending on concentration,…
Abstract Number: 1314 • ACR Convergence 2025
Protein-Specific Anti-Malondialdehyde-Acetaldehyde Antibodies and Cardiovascular Disease Outcomes in Rheumatoid Arthritis
Julia King¹, Michael Duryee¹, Punyasha Roul², Katherine Wysham³, Grant Cannon⁴, Gary Kunkel⁵, John Richards⁶, Isaac Smith⁷, Beth Wallace⁸, Gail Kerr⁹, Andreas Reimold¹⁰, Pascale Schwab¹¹, Daniel Anderson¹², Wenxian Zhou¹³, Joshua Baker¹⁴, Ted Mikuls¹, Bryant England¹ and Tate Johnson¹, ¹University of Nebraska Medical Center, Omaha, NE, ²UNMC, Omaha, NE, ³VA PUGET SOUND/UNIVERSITY OF WASHINGTON, Seattle, WA, ⁴University of Utah and Salt Lake City VA, Salt Lake City, UT, ⁵University of Utah and George E Wahlen VAMC, Salt Lake City, UT, ⁶Veterans Affairs Pittsburgh Healthcare System, Pittsburgh, PA, ⁷Duke University Hospital, Durham, NC, ⁸Michigan Medicine, VA Ann Arbor Healthcare System, Ann Arbor, MI, ⁹Washington DC VAMC/Georgetown and Howard Universities, Washington, DC, ¹⁰Dallas VA Medical Center, Dallas, TX, ¹¹VA Portland and Oregon Health & Science University, Portland, OR, ^120587964, Durham, NC, ¹³University of Nebraska Medical Center, Bellevue, NE, ¹⁴University of Pennsylvania, Philadelphia, PA
Background/Purpose: Cardiovascular disease (CVD) remains the leading cause of death in rheumatoid arthritis (RA), driven primarily by atherosclerotic CVD (ASCVD) and heart failure (HF). Malondialdehyde-acetaldehyde…
Abstract Number: 1227 • ACR Convergence 2025
The Composition of Circulating Immune Cells is Associated with Nociplastic Pain in Patients with Rheumatoid Arthritis
Tyler Therron¹, Meghan Mayer², Cecilia Stumpf³, Gelis Galarcé Lugo⁴, Morgan Langereis⁵, Kathleen Aren⁶, Mary Carns⁵, Cally Mills⁵, Cheol Min Lee⁷, Vanessa Manada De Lobos², Carla Marie Cuda⁵, Yvonne Lee⁵ and Deborah Rachelle Winter⁸, ¹Northwestern Feinberg School of Medicine, Chicago, IL, ²Northwestern University, Chicago, ³Northwestern University, Elmhurst, IL, ⁴Northwestern University Feinberg School of Medicine, Zionsville, IN, ⁵Northwestern University, Chicago, IL, ⁶Northwestern University Division of Rheumatology, Chicago, IL, ⁷Northwestern University Feinberg School of Medicine, Chicago, IL, ⁸Northwestern University, Skokie, IL
Background/Purpose: Over half of patients with RA report clinically meaningful pain, despite treatment with disease-modifying antirheumatic drugs (DMARDs). While joint inflammation is a known cause…
Abstract Number: 1063 • ACR Convergence 2025
Gender, Racial, and Geographic Trends in Mortality from Interstitial Lung Diseases Among Patients With Rheumatoid Arthritis in the U.S. Population, 1999–2020
Farheen Malik¹, Jawad Ahmed², Mandar Shah¹, Ritika Uttam³ and Muhammad Fahimuddin¹, ¹Jacobi Medical Center, Bronx, NY, NY, ²Northwest Health Porter, Valpraiso, IN, ³Jacobi Medical Center, Bronx, NY
Background/Purpose: Rheumatoid arthritis (RA) is a common autoimmune disease affecting up to 1.0% of the US population. RA is most commonly associated with synovial inflammation…
Abstract Number: 1004 • ACR Convergence 2025
Single-Cell Analysis Reveals Tissue Resident Memory T Cells Heterogeneity in the Joint
Yang Yang¹, Yusuke Miyashita², Madison Mangin³, Kellen Winden¹, Peter Nigrovic² and Margaret Chang¹, ¹Boston Children's Hospital, Boston, MA, ²Boston Children's Hospital, Brookline, MA, ³Boston Children's Hospital, St Simons Island, GA
Background/Purpose: Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by joint-specific memory, the phenomenon in which arthritis repeatedly flares in the same joints. We…
Abstract Number: 0904 • ACR Convergence 2025
SLAMF7 Drives Plasma Cell Differentiation in Rheumatoid Arthritis Synovium.
Jabea Ekabe¹, Ken Yasaka², Ruoqiao Wang³, Nida Pellett⁴, Javier Rangel-Moreno², Juilee Thakar³ and Jennifer Anolik⁴, ¹University of Rochester, Brighton, NY, ²University of Rochester, Rochester, NY, ³University of Rochester, Rochester NY, ⁴University of Rochester Medical center, Rochester, NY
Background/Purpose: B cells contribute to rheumatoid arthritis (RA) pathogenesis through antibody-dependent and -independent mechanisms. Thus, identifying regulators of B cell fate in RA is essential…
Abstract Number: 0815 • ACR Convergence 2025
Neuropathic-like Pain Characteristics Predict Worse Pain Outcomes in Early Rheumatoid Arthritis: a Prospective Cohort Study with Embedded Neuroimaging Evaluation
Eoin Kelleher¹, Amanda Wall¹, Isabelle Brennan², Robert Murphy¹, Antonella Delmis¹, John Davis³, Vishvarani Wanigasekera⁴, Irene Tracey¹ and Anushka Irani⁵, ¹University of Oxford, Oxford, United Kingdom, ²University of Cambridge, Cambridge, United Kingdom, ³Mayo Clinic, Rochester, MN, ⁴University of Oxford, Oxford, ⁵Mayo Clinic, Jacksonville, FL
Background/Purpose: Despite effective control of inflammation in rheumatoid arthritis (RA), persistent and severe pain remains a clinical challenge. Dysregulated pain processing in the central nervous…
Abstract Number: 0501 • ACR Convergence 2025
Phase 1b Study of SBT777101, an Engineered CAR-T-Regulatory Cell Product, in Patients With Rheumatoid Arthritis: Interim Demographics and Safety
Sarah Baxter¹, Ari Bitton², Victor Yuan², Fawad Aslam³, Gregory Challener⁴, Jonathan Graf⁵, Melissa Griffith⁶, Tamiko Katsumoto⁷, Minna Kohler⁸, Elena Massarotti⁹, Larry Moreland¹⁰, Allison Rosenthal¹¹, Jeffrey Sparks⁹, Steven Vlad¹², Janeth Yinh¹³, Andrew Clauw¹⁴, Sally Arai¹⁵, Alexander Carvidi⁵, Angela Chavez¹⁶, Olivia Gabriel¹⁷, Rita Gyurko¹⁷, Megan Hall¹⁸, Jennifer Seifert¹⁹, Emma Stainton¹⁵, Michelle Blake¹, Sabrina Fox-Bosetti², Mark Fromhold¹, Mindy Jensen²⁰, Herve Lebrec², Sean O'Bryan², Amanda Pace²¹, Mei-Lun Wang², Yuanyuan Xiao², Joseph Arron² and Jeffrey Bluestone²², ¹Sonoma Biotherapeutics, Seattle, WA, ²Sonoma Biotherapeutics, San Francisco, CA, ³Mayo Clinic, Arizona, Scottsdale, AZ, ⁴MGH, Boston, MA, ⁵UCSF, San Francisco, CA, ⁶University of Colorado, Aurora, CO, ⁷Division of Immunology and Rheumatology, Stanford University, Millbrae, CA, ⁸Massachusetts General Hospital, Harvard Medical School, Boston, MA, ⁹Brigham and Women's Hospital, Boston, MA, ¹⁰University of Colorado, Denver, CO, ¹¹Mayo Clinic, Phoenix, ¹²Tufts Medicine, Boston, MA, ¹³Massachusetts General Hospital, Boston, MA, ¹⁴Univ of Colorado, Aurora, CO, ¹⁵Stanford, Palo Alto, CA, ¹⁶Tufts, Boston, MA, ¹⁷BWH, Boston, MA, ¹⁸Mayo, Scottsdale, AZ, ¹⁹University of Colorado and Oklahoma Medical Research Foundation, Aurora, CO, ²⁰Sonoma Bio, Seattle, ²¹Sonoma Bio, Seattle, WA, ²²Sonoma Biotherapeutics, South San Francisco, CA
Background/Purpose: Regulatory T cells (Tregs) modulate inflammation, maintain self-tolerance, and promote tissue repair, and thus hold promise as a versatile therapeutic tool. Autologous polyclonal Tregs…
Abstract Number: 0483 • ACR Convergence 2025
Safety of JAK inhibitors (JAKi) in chronic inflammatory arthritis (CIA): an observational study
Clara De Miguel¹, Héctor Vega², Marta Sánchez², Esther Toledano³, Pedro Pablo Bermejo⁴, Leonor Laredo⁵, José Alberto Peña⁶, María Teresa Benítez⁷, DALIFER FREITES⁸, LETICIA LEON⁹ and lydia Abasolo Alcazar¹⁰, ¹Rheumatology Service, San Carlos Clinical Hospital, Madrid, Spain, ²Complutense University of Madrid, Madrid, Spain, ³Rheumatology Service, San Carlos Clinical Hospital, Madrid, Spain, ⁴Clinical Pharmacology Service, San Carlos Clinical Hospital, MADRID, Madrid, Spain, ⁵Hospital Clinico San Carlos, MADRID, Madrid, Spain, ⁶Pharmacy Service San Carlos Clinical Hospital, MADRID, Madrid, Spain, ⁷San Carlos Clinical Hospital, MADRID, Madrid, Spain, ⁸Rheumatology Service, San Carlos Clinical Hospital, Madrid, Madrid, Spain, ⁹Fundación Investigación Biomédica Hospital Clínico San Carlos, IdISSC; Universidad Camilo Jose Cela, MADRID, Madrid, Spain, ¹⁰IdISSC. HCSC, Madrid, Madrid, Spain
Background/Purpose: Rheumatoid arthritis (RA), psoriatic arthritis (PsA), and spondyloarthritis (SpA) are chronic inflammatory arthritis (CIAs). Janus kinase inhibitors (JAKis) have emerged as a promising therapeutic…
Abstract Number: 0467 • ACR Convergence 2025
A Machine Learning Classifier Leveraging Anti-RA33, Anti-PAD4, and Conventional Biomarkers Enhances Diagnostic Performance Characteristics for RA
Vasileios Kyttaris¹, Sepehr Taghavi², Clayton Nagle³, Christine Schleif³, Brittany Partain⁴ and Tyler O'Malley⁵, ¹Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, ²Exagen Inc, Escondido, CA, ³Exagen, Carlsbad, CA, ⁴Exagen, Boston, MA, ⁵Exagen, Vista, CA
Background/Purpose: Early diagnosis of rheumatoid arthritis (RA) enables prompt intervention, significantly mitigating risk for disease progression, joint damage, and associated morbidity. Conventional biomarkers, anti-CCP and…

1
2
3
…
219
Next Page »

All abstracts accepted to PRYSM are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 6:00 PM CT on March 18. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].